GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.57
−1.12%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$10.56
From 52W high−96.51%
Volume38767.00
Market cap$64.65M
P/E (TTM)—
P/S (TTM)1.2x
Div yield—
Key dataOct 30, 2026
Open
$10.56
From 52W high
−96.51%
Volume
38767.00
Market cap
$64.65M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
55.6
MomentumView details →
1D Return
−1.12%
YTD Return
−95.61%
SummaryUpdated Jun 1, 2026
Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in San Diego, California. The company went public in February 2019 and focuses on discovering, acquiring, developing, and commercializing innovative therapeutics targeting immunology, inflammation, and oncology. Originally incorporated as FSG Bio, Inc., the company changed its name to Gossamer Bio in 2017. Gossamer Bio operates as a development-stage biotechnology company with multiple drug candidates in various phases of clinical trials, positioning itself to address significant unmet medical needs in rare and serious diseases.
Similar companies
Latest newsMore news →
Gossamer Bio submitted a New Drug Application to the U.S. FDA in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension.37d agoGossamer Bio, Inc. appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with an annual base salary of $40,000 and an initial equity award to be determined later.44d agoGossamer Bio, Inc. filed a Certificate of Amendment with the Delaware Secretary of State to effect a 1-for-80 reverse stock split.49d ago